Abstract | Background: Objective: Unlike minocycline, which is a second-generation tetracycline, sarecycline, a narrow-spectrum third-generation tetracycline-class agent approved to treat acne vulgaris, has demonstrated low rates of vestibular-related adverse events in clinical trials. In this work, we evaluate the brain-penetrative and lipophilic attributes of sarecycline in 2 non-clinical studies and discuss potential associations with vestibular adverse events. Methods: Rats received either intravenous sarecycline or minocycline (1.0 mg/kg). Blood-brain penetrance was measured at 1, 3, and 6 h postdosing. In another analysis, the lipophilicity of sarecycline, minocycline, and doxycycline was measured via octanol/water and chloroform/water distribution coefficients (logD) at pH 3.5, 5.5, and 7.4. Results: Conclusion: The reduced blood-brain penetrance and lipophilicity of sarecycline compared with other tetracyclines may explain low rates of vestibular-related adverse events seen in clinical trials.
|
Authors | Ayman Grada, James Q Del Rosso, Angela Y Moore, Linda Stein Gold, Julie Harper, Giovanni Damiani, Katharina Shaw, Sabine Obagi, Raidah J Salem, S Ken Tanaka, Christopher G Bunick |
Journal | Frontiers in medicine
(Front Med (Lausanne))
Vol. 9
Pg. 1033980
( 2022)
ISSN: 2296-858X [Print] Switzerland |
PMID | 36569144
(Publication Type: Journal Article)
|
Copyright | Copyright © 2022 Grada, Del Rosso, Moore, Stein Gold, Harper, Damiani, Shaw, Obagi, Salem, Tanaka and Bunick. |